General MedicationsTABLETGeneric
SITAGLIPTIN
SITAGLIPTIN
Standard Dose
25MG
Max Dose
Refer to approved labeling
Primary Use
Review priority: STANDARD Marketing status: None (Tentative Approval)
Summary
Approval overview SITAGLIPTIN is listed in Drugs@FDA under application 216057 (ANDA).
Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN Form and strength TABLET - 25MG Sponsor LAURUS LABS LTD Submission history Latest submission status date: 2025-11-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview SITAGLIPTIN is listed in Drugs@FDA under application 216057 (ANDA). Review priority: STANDARD Marketing status: None (Tentative Approval) Active ingredient SITAGLIPTIN Form and strength TABLET - 25MG Sponsor LAURUS LABS LTD Submission history Latest submission status date: 2025-11-12 00:00:00. Submission type: ORIG.
Monitoring
- • Marketing status: None (Tentative Approval)
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.